Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis with Pseudomonas aeruginosa
2009-014412-35Phase 2Unknown
- Sponsor
- Paradigm Biopharmaceuticals
- Start
- Oct 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ciprofloxacin in bronchiectasis and Pseudomonas aeruginosa airway infection (3 arms), sponsored by Paradigm Biopharmaceuticals. Primary endpoints: Mean change in P. aeruginosa sputum density from baseline to Day 28, Microbiological superiority of CFI 100 mg versus placebo and 1 more. Status: unknown.
02
Drugs
ciprofloxacin
03
Conditions
bronchiectasisPseudomonas aeruginosa airway infection
Beyond the preview
Go deeper on 2009-014412-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014412-35.